Firstly, we evaluated 5 established ALL cell lines with wild type (n = 3) or mutant (n = 2) TP53 mutation status to determine sensitivity to the first-in-class, selective WEE1 kinase inhibitor adavosertib (AZD1775) (Fig. 1A). Here, TP53 is linked to acute lymphoblastic leukemia.